Kiniksa Pharmaceuticals, Ltd.KNSANASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank56
3Y CAGR+13.9%
5Y CAGR-2.4%
Year-over-Year Change
Research and development spending
3Y CAGR
+13.9%/yr
vs -6.7%/yr prior
5Y CAGR
-2.4%/yr
Recent acceleration
Acceleration
+20.7pp
Accelerating
Percentile
P56
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $96.85M | -13.2% |
| 2024 | $111.62M | +46.7% |
| 2023 | $76.10M | +16.2% |
| 2022 | $65.49M | -34.0% |
| 2021 | $99.30M | -9.4% |
| 2020 | $109.64M | -17.5% |
| 2019 | $132.93M | +53.5% |
| 2018 | $86.60M | +53.7% |
| 2017 | $56.36M | +223.2% |
| 2016 | $17.44M | - |